Table 2 Characteristics of children with HCV infection.
Non-treatment group (n = 11) | Treatment group (n = 25) | p-value | |
|---|---|---|---|
Male, n, (%) | 4 (36.3) | 13 (52.0) | n.s. |
Age at this study, y, mean ± SD | 8.1 ± 2.6 | 16.6 ± 4.6 | p < 0.01 |
Past medical history other than hepatitis C, n (%) | 1 (9.1) | 3 (12.0) | n.s. |
Age at infection detected, y, median (interquadrant range) | 0 (0–1) | 0 (0–1.25) | n.s. |
Transmission mode (%) | |||
Vertical/perinatal | 11 (100) | 25 (100) | n.s. |
Age at initial treatment, y, mean ± SD | 10.9 ± 4.3 | ||
Number of treatment (%) | |||
0 | 11 (100) | 0 (0) | |
1 | 0 (0) | 22 (88.0) | |
2 | 0 (0) | 2 (8.0) | |
3 | 0 (0) | 1 (4.0) | |
Therapeutic agents (%) | |||
IFN | 6 (24.0) | ||
Peg-IFN + RBV | 12 (48.0) | ||
Peg-IFN + RBV + SMV | 2 (8.0) | ||
DAA | 8 (32.0) | ||
Moderate or severe adverse events (%) | 10 (40.0) | ||
Viral clearance (%) | 25 (100) | ||
